Preclinical studies show that bladder tumour cell lines with FGFR3 point mutations or gene fusions are sensitive to FGFR inhibition [17, 18, 19], and good responses of bladder cancer patients in some phase 1 trials [20] have led to trials of FGFR inhibitors in patients with FGFR‐altered urothelial carcinoma, with promising results [21, 22]. This evidence concerns the gene FGFR3 and urothelial carcinoma.